Skip to main content
SYS · ONLINEPASS · 63.0%
Open Assay
Independent Testing / Est. 2026
BATCH04·26·B
PASS63.0%
N27
PeptidesLongevity, ImmuneTestagen

Testagen

/ Khavinson-tradition tetrapeptide (Lys-Glu-Asp-Gly); proposed thymus / immune bioregulator
SPECULATIVEN = 0 · TESTING PENDING

ALIAS · KEDG · Lys-Glu-Asp-Gly · Thymic peptide bioregulator

Pass rate
0
Samples
0
Suppliers
Research use onlyAny dose figures below describe what specific cited studies used, reported factually. Nothing on this page is guidance for human use.READ FIRST →

Terms in this page you can click for a plain-English popup: , , , , , , , .

§ A · Identity
Primary sequenceKEDG
MW · CLASS · Khavinson-tradition tetrapeptide (Lys-Glu-Asp-Gly); proposed thymus / immune bioregulatorCATEGORY · Longevity, Immune

Tier 4. Khavinson-tradition tetrapeptide Lys-Glu-Asp-Gly (KEDG) marketed in vendor channels with thymic / immune positioning. The Khavinson-group literature places KEDG within the broader tetrapeptide bioregulator family; primary data on the KEDG tetrapeptide specifically is sparse and originating-group-authored.

§ B · Mechanism of action

Testagen is the synthetic tetrapeptide Lys-Glu-Asp-Gly (KEDG). Within the Khavinson-tradition framework the proposed mechanism is tissue-specific regulation of thymic and immune-related cell gene expression. Reported effects in the Khavinson literature include modulation of immune-cell differentiation markers in in-vitro and rodent preparations.

§ C · Human clinical evidence

Tier 4. PubMed-indexed primary literature on KEDG specifically is sparse and from the Khavinson group. No human clinical-trial data.

§ F · Safety signal

No formal human safety database. The thymic / immune positioning implies effects on immune cell populations that are not characterised in published Western literature; relevant interaction risk for subjects on immunomodulatory medication cannot be assessed from the available record.

§ H · Regulatory status

Regulatory status

FDA status:
Not FDA-approved
§ I · Notable gaps and controversies

The Khavinson school (Saint-Petersburg Institute of Bioregulation and Gerontology) has published an extensive body of work on short-peptide 'bioregulators' derived from animal-tissue extracts, with a unifying claim that tissue-specific tetrapeptides (and shorter motifs) regulate gene expression and tissue-specific cell function. The corpus is Russian-origin and substantially self-cited; independent Western replication of the foundational findings has not been established.

Testagen / KEDG sits in a vendor nomenclature that overlaps with the broader tissue-specific tetrapeptide family marketed by the same channels. Independent verification of the vendor preparation's actual peptide content is not available, and the thymic / immune effect claim is not supported by independent Western data.